Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
Early molecular response has been associated with clinical outcome in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors. The BCR-ABL1 transcript rate decline from baseline to 3 months has been demonstrated to be more predictive than a single BCR-ABL1 level at 3 months (...
| Publicado en: | Annals of Hematology Vol. 98; no. 5; pp. 1159 - 1169 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
May2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135891204&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 135891204 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09395555 1WU jtl: Annals of Hematology issn: 09395555 maglogo: N pubinfo: dt: May2019 vid: 98 iid: 5 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 135891204 135891204 NLM30798348 135891204 10.1007/s00277-019-03633-x NLM30798348 135891204 ppf: 1159 ppct: 10 formats: tig: atl: Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line. aug: au: Dulucq, Stephanie Etienne, Gabriel Morisset, Stephane Klein, Emilie Chollet, Claudine Robbesyn, Fanny Turcq, Beatrice Tigaud, Isabelle Hayette, Sandrine Nicolini, Franck E. Mahon, François-Xavier affil: Laboratory of Hematology, Bordeaux University Hospital, Avenue de Magellan, 33604, Pessac Cedex, France sug: subj: Proteins RNA Proteins Metabolism Leukemia, Myeloid, Chronic RNA Metabolism Leukemia, Myeloid, Chronic Mortality Leukemia, Myeloid, Chronic Metabolism Leukemia, Myeloid, Chronic Drug Therapy Male Prognosis Survival Aged Female Middle Age Adult Human Aged: 65+ years Middle Aged: 45-64 years Adult: 19-44 years Male Female ab: Early molecular response has been associated with clinical outcome in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors. The BCR-ABL1 transcript rate decline from baseline to 3 months has been demonstrated to be more predictive than a single BCR-ABL1 level at 3 months (M3). However, it cannot be used routinely because ABL1, as an internal gene control, is not reliable for BCR-ABL1 quantification above 10%. This study aimed to compare clinical outcome and molecular response of chronic phase CML patients, depending on the percentage of BCR-ABL1 transcript decrease from month 3 to month 6 using ABL1 as an internal control gene. Two hundred sixteen chronic phase CML patients treated with imatinib 400 mg for whom M3 and month 6 molecular data were available were included in the study. Associations with event-free (EFS), failure-free (FFS), progression-free (PFS), and overall survivals (OS) molecular response 4 log and 4.5 log were assessed. The percentage of BCR-ABL1 decline from month 3 to month 6 was significantly linked to the EFS and the FFS (p < 0.001). A common cut-off of 67% of decline predicted the better risk of event. Patients with a decrease below 67% have worse EFS and FFS as compared to those having a higher decrease (p < 0.001). The impact was confirmed by multivariate analysis. Since the slope between diagnosis and 3 months cannot be reliable using ABL1 as an internal gene control, the second decline rate of BCR-ABL1 transcript between month 3 and month 6 could efficiently identify patients at higher risk of event. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|